Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances Short-Term Debt repayments Wages, Salaries and Other

Journey Medical (DERM) Long-Term Debt Repayments (2021 - 2025)

Journey Medical filings provide 5 years of Long-Term Debt Repayments readings, the most recent being $625000.0 for Q1 2025.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $625000.0 in Q1 2025 year-over-year; TTM through Dec 2025 was $625000.0, a 109.8% increase, with the full-year FY2025 number at $625000.0, down 50.0% from a year prior.
Long-Term Debt Repayments hit $625000.0 in Q1 2025 for Journey Medical, roughly flat from $625000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $2.5 million in Q3 2021 to a low of -$9.0 million in Q3 2023.
Median Long-Term Debt Repayments over the past 5 years was $1.0 million (2021), compared with a mean of $283333.3.
Biggest five-year swings in Long-Term Debt Repayments: rose 11.11% in 2022 and later plummeted 1000.0% in 2023.
Journey Medical's Long-Term Debt Repayments stood at $2.5 million in 2021, then decreased by 20.0% to $2.0 million in 2022, then crashed by 550.0% to -$9.0 million in 2023, then skyrocketed by 106.94% to $625000.0 in 2024, then changed by 0.0% to $625000.0 in 2025.
The last three reported values for Long-Term Debt Repayments were $625000.0 (Q1 2025), $625000.0 (Q4 2024), and -$9.0 million (Q3 2023) per Business Quant data.